Indoor Biotechnologies, Inc., Charlottesville, VA, United States.
National Institute of Environmental Health Sciences, Durham, NC, United States.
Front Immunol. 2020 Sep 2;11:2067. doi: 10.3389/fimmu.2020.02067. eCollection 2020.
The development of allergic disease involves the production of IgE antibodies upon allergen exposure in a process called sensitization. IgE binds to receptors on the surface of mast cells and basophils, and subsequent allergen exposure leads to cross-linking of IgE antibodies and release of cell mediators that cause allergy symptoms. Although this process is quite well-understood, very little is known about the epitopes on the allergen recognized by IgE, despite the importance of the allergen-antibody interaction for the allergic response to occur. This review discusses efforts to analyze allergen-antibody interactions, from the original epitope mapping studies using linear peptides or recombinant allergen fragments, to more sophisticated technologies, such as X-ray crystallography and nuclear magnetic resonance. These state-of-the-art approaches, combined with site-directed mutagenesis, have led to the identification of conformational IgE epitopes. The first structures of an allergen (egg lysozyme) in complex with Fab fragments from IgG antibodies were determined in the 1980s. Since then, IgG has been used as surrogate for IgE, due to the difficulty of obtaining monoclonal IgE antibodies. Technical developments including phage display libraries have contributed to progress in epitope mapping thanks to the isolation of IgE antibody constructs from combinatorial libraries made from peripheral blood mononuclear cells of allergic donors. Most recently, single B cell antibody sequencing and human hybridomas are new breakthrough technologies for finally obtaining human IgE monoclonal antibodies, ideal for epitope mapping. The information on antigenic determinants will facilitate the design of hypoallergens for immunotherapy and the investigation of the fundamental mechanisms of the IgE response.
变应性疾病的发展涉及到在致敏过程中,在过敏原暴露下产生 IgE 抗体。IgE 与肥大细胞和嗜碱性粒细胞表面的受体结合,随后过敏原暴露导致 IgE 抗体交联和细胞介质释放,从而引起过敏症状。尽管这个过程已经被很好地理解,但对于 IgE 识别的过敏原表位知之甚少,尽管过敏原-抗体相互作用对于过敏反应的发生非常重要。这篇综述讨论了分析过敏原-抗体相互作用的努力,从最初使用线性肽或重组过敏原片段进行表位作图研究,到更复杂的技术,如 X 射线晶体学和核磁共振。这些最先进的方法,结合定点突变,已经导致了构象 IgE 表位的鉴定。第一个过敏原(卵溶菌酶)与 IgG 抗体 Fab 片段复合物的结构在 20 世纪 80 年代被确定。从那时起,由于获得单克隆 IgE 抗体的困难,IgG 一直被用作 IgE 的替代品。包括噬菌体展示文库在内的技术发展,由于从过敏供体的外周血单核细胞组合文库中分离出 IgE 抗体构建体,促进了表位作图的进展。最近,单 B 细胞抗体测序和人杂交瘤是获得人 IgE 单克隆抗体的新突破技术,非常适合进行表位作图。抗原决定簇的信息将有助于设计用于免疫治疗的低变应原,并研究 IgE 反应的基本机制。